Finance
2024.04.08
Lumosa Partners with Center Lab to Invest in GenEditBio, Targeting Gene Therapy
Finance
2024.01.22
Lumosa Launching LT3001 Phase 2 Trials in Multiple EU Countries
Finance
2023.12.05
Lumosa’s Lead Candidate LT3001 for Acute Ischemic Stroke Approaching Key Milestone, Targeting Unblinding in Late 2024
Finance
2023.11.09
LT1001 Long-Acting Analgesic Injection Licensed in India
Corporate
2023.09.26
Lumosa's LT1001 Receives Approval from Brunei
Expanding its presence in Southeast Asian market
Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO